• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

TWiV 1020: Clinical update with Dr. Daniel Griffin
In his weekly clinical update, Dr. Griffin discusses guidance on measles during the summer travel season, the Infectious Diseases Society of America guidelines on the diagnosis of COVID-19: antigen testing, SARS-CoV-2 variants and age-dependent infection rates among household and nonhousehold contacts, effect of COVID-19 vaccination on household transmission of SARS-COV-2 in the Omicron era, incidence of myopericarditis after mRNA COVID-19 vaccination, intrinsic and effective severity of COVID-19 cases infected with the ancestral strain and Omicron BA.2 variant in Hong Kong, safety, immunogenicity and protection of heterol...
Source: This Week in Virology - MP3 Edition - July 1, 2023 Category: Virology Authors: Vincent Racaniello Source Type: podcasts

TWiV 951: Clinical update with Dr. Daniel Griffin
In his weekly clinical update Dr. Griffin discusses Influenza incidence and vaccine effectiveness during the southern hemisphere influenza season in Chile, Nirsevimab for prevention of RSV infection in healthy late-preterm and term infants, severe Monkeypox in hospitalized patients, reinfections with different SARS-CoV-2 Omicron subvariants, impact of community masking on COVID-19 in Bangladesh, unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses, antibody responses to Omicron BA.4/BA.5 bivalent mRNA vaccine booster shot, immunogenicity of bivalent mRNA vaccine boosters, lo...
Source: This Week in Virology - MP3 Edition - November 5, 2022 Category: Virology Authors: Vincent Racaniello Source Type: podcasts

Molecules, Vol. 27, Pages 6934: Potential Therapeutic Approach of Melatonin against Omicron and Some Other Variants of SARS-CoV-2
Yoshikazu Yonei The Omicron variant (B.529) of COVID-19 caused disease outbreaks worldwide because of its contagious and diverse mutations. To reduce these outbreaks, therapeutic drugs and adjuvant vaccines have been applied for the treatment of the disease. However, these drugs have not shown high efficacy in reducing COVID-19 severity, and even antiviral drugs have not shown to be effective. Researchers thus continue to search for an effective adjuvant therapy with a combination of drugs or vaccines to treat COVID-19 disease. We were motivated to consider melatonin as a defensive agent against SARS-CoV-2 because of...
Source: Molecules - October 16, 2022 Category: Chemistry Authors: Rahima Begum A. N. M. Mamun-Or-Rashid Tanzima Tarannum Lucy Md. Kamruzzaman Pramanik Bijon Kumar Sil Nobendu Mukerjee Priti Tagde Masayuki Yagi Yoshikazu Yonei Tags: Review Source Type: research

Protective Effect of Melatonin Administration against SARS-CoV-2 Infection: A Systematic Review
Conclusions: (1) melatonin has anti-inflammatory, antioxidant, immunomodulatory, and Mpro and MMP9 protein-inhibitory activity. (2) It has been shown to have a wide margin of safety. (3) The contributions reviewed make it an effective therapeutic alternative in the treatment of SARS-CoV-2 infection. (4) Further clinical trials are recommended to clearly define the administration protocol.PMID:35723382 | PMC:PMC8929125 | DOI:10.3390/cimb44010003
Source: Current Issues in Molecular Biology - June 20, 2022 Category: Molecular Biology Authors: Antonio Molina-Carballo Rafael Palacios-L ópez Antonio Jerez-Calero Mar ía Carmen Augustín-Morales Ahmed Agil Antonio Mu ñoz-Hoyos Antonio Mu ñoz-Gallego Source Type: research

Melatonin and REGN-CoV2 combination as a vaccine adjuvant for Omicron variant of SARS-CoV-2
Mol Biol Rep. 2022 Apr 7. doi: 10.1007/s11033-022-07419-9. Online ahead of print.ABSTRACTThe omicron variant (B.529) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which emerged in late 2021, caused panic worldwide due to its contagiousness and multiple mutations in the spike protein compared to the Delta variant (B.617.2). There is currently no specific antiviral available to treat Coronavirus disease 2019 (COVID-19). However, studies on neutralizing monoclonal antibodies (mAb) developed to fight COVID-19 are growing and gaining traction. REGN-COV2 (Regeneron or imdevimab-casirivimab combination), wh...
Source: Molecular Biology Reports - April 7, 2022 Category: Molecular Biology Authors: Ismail Celil Haskologlu Emine Erdag Serkan Sayiner Nurettin Abacioglu Ahmet Ozer Sehirli Source Type: research